Lv11
90 积分 2024-01-22 加入
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
5小时前
已完结
RET revisited: expanding the oncogenic portfolio
2个月前
已完结
Reversing “Flip-Flop” Phenomenon of 131I and Glucose Avidity in RET-Fusion Positive Radioiodine-Refractory Thyroid Cancer Lesions After Treatment of Pralsetinib
2个月前
已完结
Correction to: Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study’’ by Subbiah et al. Thyroid 2024;34(1):26–40; doi: 10.1089/thy.2023.0363
2个月前
已关闭
Efficacy and safety of pralsetinib in Chinese advanced RET-mutant medullary thyroid cancer patients
2个月前
已完结
RET-AREAL: a multi-center, real-world data analysis on the efficacy of pralsetinib in acquired RET fusion after resistance to EGFR/ALK-TKIs
3个月前
已完结
Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial
3个月前
已完结
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
3个月前
已完结
Efficacy and safety of pralsetinib in Chinese advanced RET-mutant medullary thyroid cancer patients
4个月前
已完结
Selpercatinib or Chemotherapy in RET Fusion–Positive NSCLC
4个月前
已完结
皖公网安备34019202002308
